Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study

ABSTRACT Phenoconversion is the discrepancy between genotype‐predicted phenotype and clinical phenotype, due to nongenetic factors. In oncology patients, the impact of phenoconversion on drug selection, efficacy, toxicity, and treatment outcomes is unknown. This study will assess acceptability and f...

Full description

Saved in:
Bibliographic Details
Main Authors: Rachel Conyers, Tayla Stenta, Andrew A. Somogyi, Carl Kirkpatrick, Andreas Halman, Sophie Wang, Claire Moore, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Tim Spelman, David A. Elliott, Amanda Gwee, Marliese Alexander
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical and Translational Science
Subjects:
Australia
oncology
pharmacogenomic implementation
pharmacogenomics
Phenoconversion
Online Access:https://doi.org/10.1111/cts.70209
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70209

Similar Items